These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16506048)

  • 1. Serum lipid levels in benign prostatic hyperplasia.
    Lekili M; Müezzinoğlu T; Uyanik BS; Büyüksu C
    World J Urol; 2006 Jun; 24(2):210-3. PubMed ID: 16506048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
    Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
    Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
    Zhao S; Tang J; Shao S; Yan Y
    Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benign prostate hyperplasia: average volume in southwestern Nigerians and correlation with anthropometrics.
    Badmus TA; Asaleye CM; Badmus SA; Takure AO; Ibrahim MH; Arowolo OA
    Niger Postgrad Med J; 2012 Mar; 19(1):15-8. PubMed ID: 22430596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between American Urological Association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia.
    Liu CC; Wang CJ; Huang SP; Chou YH; Wu WJ; Huang CH
    Kaohsiung J Med Sci; 2004 Jun; 20(6):273-8. PubMed ID: 15253468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
    Kwon H; Kang HC; Lee JH
    Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.
    Liao CH; Chung SD; Kuo HC
    Urology; 2011 Dec; 78(6):1373-8. PubMed ID: 21962879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A statistical study of the American Urological Association symptom index for benign prostatic hyperplasia in participants of mass screening program for prostatic diseases using transrectal sonography.
    Ukimura O; Kojima M; Inui E; Ochiai A; Hata Y; Watanabe M; Saitoh M; Watanabe H
    J Urol; 1996 Nov; 156(5):1673-8. PubMed ID: 8863568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
    Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
    Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.